Результаты поиска

[Proteasome inhibitors].

INTRODUCTION: Proteasome is involved in cell cycle and apoptosis regulation. Its deregulation could participate to oncogenesis. EXEGESIS: Bortezomib is the first proteasome inhibitor to reach clinical development. Its main adverse events are asthenia, thrombocytopenia and cumulative neurotoxicity which can limits long term use. As single agent, bortezomib displays antitumoral effects in refractory multiple myeloma and mantle cell lymphoma but has only modest activity in solid tumors. Preclinical data suggest that bortezomib could enhance antitumor activity of cytotoxics. CONCLUSION: Proteaso

Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer.

BACKGROUND: Amino-acid transporters are necessary for the tumour cell growth and survival, and have a crucial role in the development and invasiveness of cancer cells. But, it remains unclear about the prognostic significance of L-type amino-acid transporter 1 (LAT1), system ASC amino-acid transporter-2 (ASCT2), and xCT expression in patients with tongue cancer. We conducted the clinicopathological study to investigate the protein expression of these amino-acid transporters in tongue cancer. METHODS: Eighty-five patients with surgically resected tongue cancer were evaluated. Tumour sections w

Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy.

ATP-binding cassette (ABC) transporters are expressed in various human tissues and play a vital role in the efflux of various chemotherapeutic drugs. The current study has assessed genetic variants of ABCB1, ABCC1, ABCC2, and ABCG2 genes in 407 lung cancer patients undergoing platinum-based doublet chemotherapy. The association of ABCB1 (C1236 T, C3435 T, and G2677 T/A), ABCC1 (G3173 A and G2168 A),ABCC2 (G4544 A), and ABCG2 (C421 A) polymorphisms with chemotherapy-induced adverse events were assessed, and statistical analysis was conducted. Our data showed that patients harboring heterozygous

Immunotherapy for advanced or metastatic urothelial carcinoma.

BACKGROUND: Immune checkpoint inhibitors are increasingly important in the treatment algorithm for locally advanced and metastatic bladder c … e). This corresponds to 920 deaths per 1000 participants with chemotherapy (vinflunine, paclitaxel, docetaxel) and 59 fewer (95 fewer to 28 fewer) deaths per 1000 participants with immunotherapy at 36 months. Immunotherapy may have little to no effect on health-related quality of life when compared to chemotherapy (MD 4.82, 95% CI -3.11 to 12.75; I2 = 85%; …

Vitamin d: pharmacokinetics and safety when used in conjunction with the pharmaceutical drugs used in cancer patients: a systematic review.

Vitamin D has reported anti-cancer and anti-inflammatory properties modulated through gene transcription and non-genomic signaling cascades. The purpose of this review was to summarize the available research on interactions and pharmacokinetics between vitamin D and the pharmaceutical drugs used in patients with cancer. Hypercalcemia was the most frequently reported side effect that occurred in high dose calcitriol. The half-life of 25(OH)D3 and/or 1,25(OH)2D3 was found to be impacted by cimetidine; rosuvastatin; prednisone and possibly some chemotherapy drugs. No unusual adverse effects in ca

Совпадение в полном тексте источника
… Day 2: iv docetaxel (36 mg/m 2 ) repeated weekly for 6 weeks of an 8-week cycle. 37/0 | Premedication with dexamethasone 8 mg orally 12 h and 1 h before docetaxel infusion and 12 after docetaxel infusion was given. … taken orally 1 day before docetaxel. dexamethasone (4 mg orally 12 h before, 1 before, and 12 h after docetaxel administration). | Addition of weekly DN-101 did not increase the toxicity of weekly docetaxel. …

'The same old story': thoughts on authorized doses of anticancer drugs.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705–1715. 44. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695–1704. 45. … Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med 2015; 373: 123–135. 59. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 2015; 373: 1627–1639. 60. …

Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.

Majority of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases which results in significant morbidity and mortality as a result of skeletal-related events (SREs). Several bone-targeted agents are either in clinical use or in development for prevention of SREs. Bisphosphonates were the first class of drugs investigated for prevention of SREs and zoledronic acid is the only bisphosphonate that is FDA-approved for this indication. Another bone-targeted agent is denosumab which is a fully humanized monoclonal antibody that binds to the RANK-L thereby inhibi

Совпадение в полном тексте источника
… All recruited patients had either received previous docetaxel, refused docetaxel, or were ineligible for docetaxel. … Similarly, the UK TRAPEZE trial randomized men with CRPC metastatic to bone to receive one of four regimens: (1) docetaxel with prednisolone; (2) docetaxel, prednisolone, and zoledronic acid; (3) docetaxel, prednisolone, and strontium-89; or (4) docetaxel, prednisolone, zoledronic acid, and strontium …

Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective.

ObjectivesThe introduction of innovative, high-cost oncology treatments, coupled with mounting budgetary pressures, necessitates value trade-offs across cancer types. Defining value is critical to informing decision-making. A cost-value analysis tool was used to assess relative clinical value from a US perspective using multiple outcome metrics for a variety of metastatic cancers.MethodsLiterature published (January 1, 2000-August 31, 2016) was reviewed to identify outcome metrics for approved treatments for metastatic cancers. Data were extracted or derived for median and mean overall surviva

Совпадение в полном тексте источника
… 95 , 96 | NA | 2/3L | Xeloda SO14999 | Docetaxel Eribulin mesylate 97 – 100 | NA | 3L | EMBRACE | Physician’s treatment of choice Trastuzumab + docetaxel 101 – 105 | NA | 1L | Herceptin M77001 | Docetaxel Ado-trastuzumab emtansine 106 – 109 | NA | 2L+ | EMILIA | Lapatinib + capecitabine Pertuzumab + … trastuzumab + docetaxel 110 – 114 | NA | 1L | CLEOPATRA | Placebo + trastuzumab + docetaxel Trastuzumab emtansine + placebo 115 | NA | 1L | MARIANNE | Trastuzumab + taxane (docetaxel/paclitaxel) Lapatinib 116 , 117 | NA | 1L | EGF 30008 | Letrozole + placebo Lapatinib + capecitabine 118 – 121 | NA | …

Liposomal Doxorubicin in the treatment of breast cancer patients: a review.

Drug delivery systems can provide enhanced efficacy and/or reduced toxicity for anticancer agents. Liposome drug delivery systems are able to modify the pharmacokinetics and biodistribution of cytostatic agents, increasing the concentration of the drug released to neoplastic tissue and reducing the exposure of normal tissue. Anthracyclines are a key drug in the treatment of both metastatic and early breast cancer, but one of their major limitations is cardiotoxicity. One of the strategies designed to minimize this side effect is liposome encapsulation. Liposomal anthracyclines have achieved hi

Совпадение в полном тексте источника
… OS was similar: 20.6 months in the docetaxel arm and 20.5 in the combined treatment arm (HR 1.02; 95% CI, 0.86–1.22). … The incidence of hand-foot syndrome was higher in the combined treatment arm (24% versus 0%) and symptomatic cardiac toxicity was similar: 4% in the docetaxel group and 5% in the PLD-docetaxel group. …

Phytochemical-Based Nanomedicine for Advanced Cancer Theranostics: Perspectives on Clinical Trials to Clinical Use.

In the current chapter, a new strategic compilation of phytochemicals with potent antitumor properties has been addressed, most importantly focusing on cell cycle arrest and apoptotic signaling mechanism. A promising approach in tumor prevention is to eliminate cancer cells preferably via cell cycle arrest and programmed cell death with lesser harm to neighboring normal cells. Cancer cells have a survival advantage to escape apoptosis and relentlessly divide to proliferate, gearing up the cell cycle process. Recently, the use of phytochemical-derived conjugated chemotherapeutic agents has incr

Совпадение в полном тексте источника
… Docetaxel-Entrapped CriPec Nanoparticles [CriPec ® Docetaxel/CPC634] CPC634 is a nano-formulation of docetaxel adsorbed tuneable CriPec nanoparticles. … compared to docetaxel alone. …

Narrative Review of Drug-Associated Nail Toxicities in Oncologic Patients.

IntroductionNail toxicity represents one of the most common cutaneous adverse effects of both classic chemotherapeutic agents and new oncologic drugs, including targeted treatments and immunotherapy.ObjectivesWe aimed to provide a comprehensive literature review of nail toxicities derived from conventional chemotherapeutic agents, targeted therapies (EGFR inhibitors, multikinase inhibitors, BRAF and MEK inhibitors) and immune checkpoint inhibitors (ICIs), including clinical presentation, implicated drugs and approaches for prevention and management.MethodsRetrieved literature from PubMed regis

Совпадение в полном тексте источника
… Onycholysis is one of the most prevalent adverse events induced by docetaxel or paclitaxel [ 22 ]. … Docetaxel and Paclitaxel may cause koilonychia more often ( Table 5 ). Onychorrhexis is a type of longitudinal groove wherein a series of shallow and narrow furrows are present running parallel on the nail surface. Docetaxel, paclitaxel and ibrutinib may cause onychorrhexis ( Table 5 ). …

Management of bone metastasis with zoledronic acid: A systematic review and Bayesian network meta-analysis.

BACKGROUND: While considered the mainstay of treatment for specific bone metastases, ZA is used predominantly to treat osteolytic lesions. The purpose of this network meta-analysis is to compare ZA to other treatment options in its ability to improve specific clinical outcomes in patients with bone metastases secondary to any primary tumor. METHODS: PubMed, Embase and Web of Science were systematically searched from inception to May 5th, 2022. Keywords used were solid tumor, lung neoplasm, kidney neoplasm, breast neoplasm, prostate neoplasm, ZA and bone metastasis. Every randomized controlled

Совпадение в полном тексте источника
… Docetaxel and ZA 3. … mg/m2 | 50 Pan, Y [45] | 2014 | Prostate cancer | After | Docetaxel-based chemotherapy + ZA - 4 mg/ 3 weeks | 53 | Docetaxel-based chemotherapy- 75 mg/m2 of docetaxel for 21 days and placebo | 52 Pandya, K. …

Direct immunoactivation by chemotherapeutic drugs in cancer treatment.

The immune system plays a crucial role in recognizing and eliminating pathogenic substances and malignant cells in the body. For cancer treatment, immunotherapy is becoming the standard treatment for many types of cancer and is often combined with chemotherapy. Although chemotherapeutic agents are often reported to have adverse effects, including immunosuppression, they can also play a positive role in immunotherapy by directly stimulating the immune system. This has been demonstrated in preclinical and clinical studies in the past decades. Chemotherapeutics can activate immune cells through d

Совпадение в полном тексте источника
… The efficacy of the polymeric micelles loaded with docetaxel was evaluated using a subcutaneous CDX model of SGC7901 cells. Free docetaxel slightly inhibited tumor growth while the polymeric micelles loaded with docetaxel showed significantly higher efficacy at two dose levels (5 and 10 mg/kg). … Importantly, the micelle formulation of docetaxel showed more effective macrophage polarization than free docetaxel ( Figure 2D ). …

Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastases.

Bone metastases are prevalent among cancer patients and frequently cause significant morbidity. Oncology providers must mitigate complications associated with bone metastases while limiting therapy-related adverse effects and their impact on quality of life. Multiple treatment modalities, including chemotherapy, surgery, external beam radiation therapy, and radioisotopes, among others, have been recommended and utilized for palliative treatment of bone metastases. Radioisotopes such as samarium-153 are commonly used in the setting of multifocal bone metastases due to their systemic distributio

Совпадение в полном тексте источника
… of docetaxel and estramustine were given consolidation docetaxel (20 mg/m 2 × 6 weeks) and 153 Sm 37 MBq/kg (1 mCi/kg) during week 1. … Morris et al sought to characterize the safety profile better for the use of escalating doses of both docetaxel and 153 Sm-EDTMP for men with castration-resistant metastatic prostate cancer. 25 Eligible patients were randomized to six different cohorts that varied by dose of docetaxel (60–75 mg/m 2 ) …

Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan.

Rising prices of novel cancer medications are increasing the economic burden from cancer in Jordan, risking the ability of cancer patients to access lifesaving and life-extending treatments. Furthermore, in the absence of a national health technology assessment (HTA) framework, medication prices in Jordan are set based on manufacturers' pricing considerations and not a value proposition. In response to these challenges, King Hussein Cancer Center (KHCC), the de facto national cancer institute, developed a first-in-country, cancer-specific, cost-effectiveness threshold (CET) to aid institutiona

Совпадение в полном тексте источника
… + cisplatin for first-line treatment of metastatic, non-squamous EGFR+ NSCLC Docetaxel + cisplatin Developed by KHCC CDPTA 66,004 Financial risk-sharing agreement was reached Recommended Lapatinib with capecitabine for first-line treatment in HER2+ metastatic breast cancer Trastuzumab + capecitabine … Trastuzumab+ docetaxel Submitted by manufacturer/adapted by CDPTA 118,412 Financial risk-sharing agreement was reached Recommended Abiraterone for the treatment of asymptomatic or minimally symptomatic castration-resistant prostate cancer patients before chemotherapy with EGFR Prednisolone Submitted …

Parallel Toxicities: A Comparative Analysis of Chemotherapy-Induced Neutropenia and Alopecia.

Chemotherapy-induced neutropenia (CIN) and chemotherapy-induced alopecia (CIA) are significant toxicities affecting cancer patients. CIN is a potentially fatal complication of chemotherapy caused by myelosuppression and increased infection susceptibility, while CIA, although not fatal, severely affects treatment adherence and mental health. This study provides a comprehensive comparative analysis of CIN and CIA, focusing on patient, disease, treatment, and genetic risk factors. Key risk factors for CIN and CIA include age, poor performance status, body mass index (BMI), laboratory abnormalitie

Совпадение в полном тексте источника
… The combination of docetaxel with carboplatin and trastuzumab raised FN incidence to 25.1%, with 62.8% of patients developing severe neutropenia. … For instance, docetaxel combined with cyclophosphamide resulted in a CIA prevalence of 96.7–100% compared to 83.3% for docetaxel monotherapy [ 106 ]. Liposomal drug delivery has emerged as a potential strategy to reduce CIA by minimizing off-target toxicity [ 120 ]. …

Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets.

Prostate cancer (PC) is the most common cancer in men and the second leading cause of cancer-related death worldwide. Many therapeutic advances over the last two decades have led to an improvement in the survival of patients with metastatic PC, yet the majority of these patients still succumb to their disease. Antiagiogenic therapies have shown substantial benefits for many types of cancer but only a marginal benefit for PC. Ongoing clinical trials investigate antiangiogenic monotherapies or combination therapies. Despite the important role of angiogenesis in PC, clinical trials in refractory

Совпадение в полном тексте источника
… Moreover, in a phase II study of 20 patients with docetaxel-refractory mCRPC, bevacizumab was added to standard of care docetaxel [ 102 ]. Patients were treated with docetaxel 60 mg/m 2 and bevacizumab 10 mg/kg every 3 weeks. PSA declines of ≥50% were seen in 55% of patients. … A randomized phase III trial compared docetaxel plus prednisone to the merging of docetaxel, prednisone, and bevacizumab in patients who are chemotherapy-naïve [ 103 ]. …

177Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.

In this systematic review and network meta-analysis (NMA), we aimed to assess the benefits and harms of third-line (L3) treatments in randomized controlled trials (RCTs) of patients with metastatic castration-resistant prostate cancer (mCRPC). Two reviewers searched for publications from 1 January 2006 to 30 June 2021. The review analyzed seven RCTs that included 3958 patients and eight treatments. Treatment with prostate-specific membrane antigen (PSMA)-based radioligand therapy (PRLT) resulted in a 1.3-times-higher rate of median PSA decline ≥50% than treatment with abiraterone, enzalutamide

Совпадение в полном тексте источника
… Some patients in our NMA had previously been treated with several series of ADT and/or been treated with several series of docetaxel. For simplification, we lumped several treatment series of ADT/ARPI as a single endocrine treatment, and lumped repeat docetaxel series as a single line of docetaxel. … Cohort studies indicated that PRLT given as an L2 treatment before treatment with docetaxel produced a better PSA response than PRLT given as an L3 treatment after treatment with docetaxel [ 47 , 48 ]. …

Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!

BackgroundThe risk of thromboembolic events is higher among cancer patients, especially in patients undergoing chemotherapy. Cisplatin-based regimens claim to be associated with a very high thromboembolic rate. In this study, we report on our own experience with thrombosis among patients on active cisplatin-based chemotherapy.MethodsMedical records and hospital databases were searched for all the patients treated with any cisplatin-based regimen for any kind of cancer. Thrombosis was considered cisplatin-related if diagnosed any time after the first dose and up to 4 weeks after the last. The K

Совпадение в полном тексте источника
… Table 4 Thromboembolic events according to chemotherapy regimen Chemotherapy Regimen Number of Patients Thromboembolic Events (n) % Cisplatin-XRT 299 13 4.3 Cisplatin-Docetaxel-5FU 245 31 12.7 Cisplatin-Docetaxel 194 13 6.7 DHAP 180 3 1.7 Cisplatin-Etoposide 145 3 2.1 Cisplatin-5FU 120 9 7.5 BEP 116 … patients) and Cisplatin-Docetaxel (193 patients). …

Prioritising systemic cancer therapies applying ESMO's tools and other resources to assist in improving cancer care globally: the Kazakh experience.

BackgroundIn Kazakhstan, cancer is the second leading cause of death with a major public health and economic burden. In the last decade, cancer care and cancer medicine costs have significantly increased. To improve the efficiency and efficacy of cancer care expenditure and planning, the Kazakhstan Ministry of Health requested assistance from the World Health Organization (WHO) and the European Society for Medical Oncology (ESMO) to review its systemic cancer treatment protocols and essential medicines list and identify high-impact, effective regimens.Materials and methodsESMO developed a four

Совпадение в полном тексте источника
… Medicines | Setting | ESMO-MCBS score | References Chemotherapy + trastuzumab | Adjuvant or neoadjuvant HER2-positive tumours | A | 9 Trastuzumab and docetaxel + pertuzumab | Neoadjuvant HER2-overexpressed invasive ductal breast | C b | 10 , 11 Trastuzumab + docetaxel + pertuzumab | First line metastatic … minimal activity Monotherapy protocols (5-FU, docetaxel) | Second-line therapy ESMO Clinical Practice Guidelines First-line treatment 1. …